bibliographicCitation |
Iwasaki K, Shin T, Inoue T, Shibuya T, Hirai K, Ando T, Mimata H. Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2. IJU Case Rep. 2021 May;4(3):139–42. PMID: 33977240; PMCID: PMC8088879. |